Migo, W., Bošković, M. i Likić, R. (2021). The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery, 2.. doi: 10.1016/j.crphar.2021.100064
Migo, William, et al. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. https://doi.org/10.1016/j.crphar.2021.100064
Migo, William, Marko Bošković i Robert Likić. "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response." Current Research in Pharmacology and Drug Discovery 2 (2021). https://doi.org/10.1016/j.crphar.2021.100064
Migo, W., Bošković, M. i Likić, R. (2021) 'The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response', Current Research in Pharmacology and Drug Discovery, 2. doi: 10.1016/j.crphar.2021.100064
Migo W, Bošković M, Likić R. The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response. Current Research in Pharmacology and Drug Discovery [Internet]. 2021. [pristupljeno 08.10.2024.];2. doi: 10.1016/j.crphar.2021.100064
W. Migo, M. Bošković i R. Likić, "The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response", Current Research in Pharmacology and Drug Discovery, vol. 2, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:760242. [Citirano: 08.10.2024.]